<DOC>
	<DOCNO>NCT01013831</DOCNO>
	<brief_summary>This phase I trial study side effect best dose erlotinib hydrochloride prevent cancer patient precancerous lesion lung . Erlotinib hydrochloride may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Erlotinib Hydrochloride Preventing Cancer Patients With Precancerous Lesions Lung</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine low dose erlotinib ( erlotinib hydrochloride ) decrease ratio phosphorylated total epidermal growth factor receptor ( EGFR ) ( phosphorylated EGFR [ pEGFR ] /EGFR ) least 20 % subject premalignant lesion lung . This accomplish implement dose de-escalation trial erlotinib ( i.e. , 75 , 50 , 25 100 mg mouth daily 3-month period ) , determine pEGFR/EGFR ratio premalignant lesion lung epithelium immunohistochemistry . Changes pEGFR/EGFR ratio assess compare pre-treatment ( baseline ) ratio post-treatment ( 3 month ) ratio , measure paraffin embed biopsy specimen . SECONDARY OBJECTIVES : I . To determine effect erlotinib follow biomarkers potential biological relevance paraffin embed lung biopsy , p-v-akt murine thymoma viral oncogene homolog 1 ( Akt ) , p-mitogen-activated protein kinase 1 ( Erk ) , marker proliferation Ki-67 ( Ki67 ) . II . To characterize toxicity profile erlotinib cohort subject . III . To analyze model erlotinib 's pharmacokinetic/pharmacodynamic ( PK/PD ) profile . Serial blood sample draw begin end erlotinib treatment , pharmacokinetic parameter determine . The status EGFR genotype ( others gene link erlotinib PK/PD ) clinical toxicity , dose examine possible influential covariates compare experimentally measure PK profile , PD profile ( particular , pEGFR/EGFR ratio ) . The goal study determine optimal biologic concentration ( OBC ) Erlotinib associate low toxicity high effect , give subject 's pharmacogenomic profile . OUTLINE : Patients receive erlotinib hydrochloride orally ( PO ) daily ( QD ) 90 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Diagnosis premalignant lung lesion ( metaplasia dysplasia ) autofluorescent bronchoscopy ( AFB ) within 1 month Participants must &gt; = 10 pack year lifetime smoke history ; current former smoker eligible trial No contraindication treatment erlotinib additional bronchoscopies Absolute neutrophil count ( ANC ) &gt; = 1.5 x 10^9/L Platelet count &gt; = 100 x 10^9/L Creatinine level le 1.5 mg/dL Total bilirubin = &lt; 2.0 mg/dl Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 1.5 x upper limit normal ( ULN ) Alkaline phosphatase = &lt; 2.5 x ULN Must meet Eastern Cooperative Oncology Group ( ECOG ) performance status criterion 01 Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) throughout duration study 1 month follow cessation study drug ; female must begin adequate contraception immediately follow screen pregnancy test ; woman become pregnant suspect pregnant participating study , inform study physician immediately ; pregnant , immediately withdrawn study Ability understand willingness sign write institutional review board ( IRB ) approve informed consent document Subjects lifethreatening medical condition would preclude treatment intervention bronchoscopy , include , limited , unstable pulmonary function , acute cardiac failure , unstable despite medication use ; uncontrolled hypertension ; uncontrolled diabetes mellitus ; unstable coronary artery disease ; acute chronic liver disease , ongoing active infection ; psychiatric illness/social situation would limit compliance study requirement Participants evidence active cancer carcinoma situ , eligible Participants currently take medication induce inhibit cytochrome P450 , family 3 , subfamily A , polypeptide 47 ( CYP3A47 ) enzymes Participants may receive investigational agent within 3 month Participants take warfarin History allergic reaction attribute erlotinib , know hypersensitivity erlotinib , agent similar chemical biological composition erlotinib Women pregnant lactating exclude study base propose mechanism tyrosine kinase inhibition erlotinib ; erlotinib assume cause fetal harm administer pregnant woman ; unknown potential risk adverse event nurse infant secondary treatment mother erlotinib History interstitial lung disease ( ILD )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>